Stocks and InvestingStocks and Investing
Thu, November 1, 2018
Wed, October 31, 2018
Tue, October 30, 2018
Mon, October 29, 2018
Fri, October 26, 2018

Andrew Fein Upgraded (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018


Published on 2024-10-26 09:59:39 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018.

Andrew has made no other calls on VRTX in the last 4 months.



There are 5 other peers that have a rating on VRTX. Out of the 5 peers that are also analyzing VRTX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Christopher Raymond of "Raymond James" Maintained at Buy with Decreased Target to $201 on, Thursday, October 25th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $206 on, Monday, July 30th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018